title: aBETting therapeutic resistance by Wnt signaling.
abstract: BET inhibition has emerged as a promising epigenetic therapy for malignancies in the last five years, but little consensus has developed regarding what may mediate the axis between sensitivity and resistance. Two recent papers published in Nature attempt to address this question in acute myeloid leukemia (AML) and independently identify the Wnt signaling pathway as a driver and biomarker of therapeutic resistance.
authors.affiliation: Michigan Center for Translational Pathology Ann Arbor, MI 48109, USA.|Department of Pathology Ann Arbor, MI 48109, USA.
authors.forename: Carl G
authors.initials: CG
authors.lastname: Engelke
authors.affiliation: Michigan Center for Translational Pathology Ann Arbor, MI 48109, USA.|Department of Pathology Ann Arbor, MI 48109, USA.|Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.|Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI 48109, USA.|Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
authors.forename: Arul M
authors.initials: AM
authors.lastname: Chinnaiyan
mesh_terms: D000818:Animals; D001381:Azepines / Q000037:antagonists & inhibitors*; D014408:Biomarkers, Tumor; D004351:Drug Resistance / Q000502:physiology*; D051379:Mice; D023421:Models, Animal; D009369:Neoplasms / Q000628:therapy*; D014230:Triazoles / Q000037:antagonists & inhibitors*; D051153:Wnt Proteins / Q000037:antagonists & inhibitors*; D060449:Wnt Signaling Pathway / Q000187:drug effects*
chemical_list: C561695:(+)-JQ1 compound; D001381:Azepines; D014408:Biomarkers, Tumor; D014230:Triazoles; D051153:Wnt Proteins